OncoNov delivers daily updates on the latest breakthroughs in cancer research, diagnostics, clinical trials, and treatment innovations. Our mission is to keep clinicians, researchers, and patients informed with concise, reliable, and actionable insights, helping the oncology community stay ahead in the rapidly evolving landscape of cancer care.
Top-line results from the Phase 3 HERIZON-GEA-01 trial show that zanidatamab-based treatment combinations significantly improve outcomes for people with previously untreated HER2-positive locally...
A new recommendation supports approving the combination of tafasitamab, lenalidomide, and rituximab for adults with relapsed or refractory follicular lymphoma who have already received at least one...
The FLAIL-C Phase 2 trial evaluated whether adding anti-PD-1 immunotherapy to the tyrosine kinase inhibitor anlotinib could improve outcomes for patients with advanced, unresectable chondrosarcoma...
A new imaging method is helping researchers predict how cancer drugs will work in patient-derived tumor models more quickly and accurately. Precision medicine aims to match the right treatment to each...
Researchers have introduced a new AI method called MST-AI that aims to make skin cancer detection more accurate and fair for people with darker skin tones. Many current AI tools used to detect...
AMT-253, a MUC18-targeted antibody-drug conjugate, has shown encouraging results in two phase 1 melanoma studies. Among 56 evaluable melanoma patients, the overall response rate was 28.6%, with 15...
Organometallic complexes—cancer-fighting compounds built around metal-carbon bonds—are emerging as a more selective alternative to traditional platinum drugs like cisplatin. While platinum...
Thyroid cancer is rising quickly worldwide and is expected to become the fourth most common cancer by 2030. Although survival rates are high, drug resistance and reduced sensitivity to radioactive...
NaPi2b, a sodium-dependent phosphate transporter protein, is once again gaining attention as a therapeutic target for platinum-resistant ovarian cancer, where treatment options remain limited. NaPi2b...
